Khosta-2: after Covid-19, would another dangerous coronavirus have emerged?

Table of Contents

In the family of coronaviruses, here is Khosta-2. This microbe belonging to the same family as SARS-CoV-2 worries scientists. Here’s why.

The risk of seeing a new pathogen appear from nature and transmissible to humans is well understood by scientists. This is why they closely monitor the various viruses spotted around the world. Among them, a team from Washington State University’s Paul G. Allen School for Global Health has recently pointed to the harmful potential of a virus belonging to the same family of coronaviruses – sarbecoviruses – as SARS-CoV-2.

Unlike hundreds of sarbecoviruses discovered in recent years, mainly in Asia in bats, Khosta-2, discovered in Russia, does indeed have worrying characteristics. “Like SARS-CoV-2, it is able to use its spike protein to infect cells by attaching to a receptor called angiotensin-converting enzyme 2, which is found in cells. humans”, explain the American researchers. Another subject of concern: neither the serum of people vaccinated once morest Covid-19, nor that of infected patients offers protection once morest this new virus.

Danger d’association

“Fortunately, this new virus lacks certain genes necessary for pathogenesis in humans,” says Michael Letko, virologist and lead author of this work. In other words, it would not have everything necessary to trigger, as it is, a disease in our organism.

However, there is nothing to be reassured regarding. There is a real risk that this virus will recombine, that is to say associate with that of Covid-19, which has developed everything necessary to make humans sick. Indeed, “SARS-CoV-2 may very well return to nature and associate with a virus like Khosta-2 which has the potential to become an even more dangerous virus”, he adds.

This is why Michael Letko and his colleagues are urging research into broader-spectrum vaccines. “We need to develop universal vaccines to protect once morest sarbecoviruses in general, rather than working on known variants of SARS-CoV-2,” he concludes.

Leave a Replay